Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | President, Research & Develop. | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,238 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Tax withholding · Disposed 2,079 · Balance 214,238 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 21:16 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 2,079 | $7.14 | $14,852.17 |
DisclosureSEC source: 0001873394-26-000005 · wk-form4_1788470182.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,238 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:25 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 25,907 | $15.39 | $398,809.77 |
DisclosureSEC source: 0001873394-26-000003 · wk-form4_1777937098.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,317 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.6150, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2026 Filed Mar 3, 2026 23:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 7,577 | $11.76 | $89,078.24 |
DisclosureSEC source: 0001873394-26-000001 · wk-form4_1772579932.xml · nonDerivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,224 F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 3,898 | $11.66 | $45,442.49 |
DisclosureSEC source: 0001873394-26-000001 · wk-form4_1772579932.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,801 F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 83,200 | $0.00 Strike: $11.93 | $0.00 |
DisclosureSEC source: 0001873394-26-000001 · wk-form4_1772579932.xml · derivative · entry 4 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,200 Underlying: Common Stock · 83,200 shares Expires 2036-03-01 F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 55,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001873394-26-000001 · wk-form4_1772579932.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,699 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:03 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,760 | $5.43 | $9,557.15 |
DisclosureSEC source: 0001873394-25-000003 · wk-form4_1757019782.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,899 F1 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:58 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 6,138 | $11.68 | $71,683.25 |
DisclosureSEC source: 0001689375-25-000012 · wk-form4_1741125479.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,659 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:58 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 90,800 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001689375-25-000012 · wk-form4_1741125479.xml · derivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,800 Underlying: Common Stock · 90,800 shares Expires 2035-03-01 F4 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2029. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:58 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 60,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-25-000012 · wk-form4_1741125479.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,797 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| December 03, 2024 Filed Dec 3, 2024 22:24 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 11,703 | $20.15 | $235,786.19 |
DisclosureSEC source: 0001689375-24-000067 · wk-form4_1733264681.xml · nonDerivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,997 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 22:24 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 4,088 | $20.26 | $82,833.51 |
DisclosureSEC source: 0001689375-24-000067 · wk-form4_1733264681.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,700 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 22:24 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 100 | $20.00 | $2,000.00 |
DisclosureSEC source: 0001689375-24-000067 · wk-form4_1733264681.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,788 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. Read SEC document |
| November 13, 2024 Filed Nov 13, 2024 21:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,700 | $20.04 | $54,108.81 |
DisclosureSEC source: 0001689375-24-000066 · wk-form4_1731534539.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,888 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,409 | $20.01 | $28,191.13 |
DisclosureSEC source: 0001689375-24-000066 · wk-form4_1731534539.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,588 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2024 Filed Nov 6, 2024 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,745 | $19.32 | $53,023.52 |
DisclosureSEC source: 0001689375-24-000064 · wk-form4_1730929001.xml · nonDerivative · entry 4 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,997 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.11 to $19.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2024 Filed Nov 6, 2024 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 9,554 | $18.71 | $178,752.47 |
DisclosureSEC source: 0001689375-24-000064 · wk-form4_1730929001.xml · nonDerivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,742 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.08 to $19.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 5,171 | $18.18 | $94,006.19 |
DisclosureSEC source: 0001689375-24-000064 · wk-form4_1730929001.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,296 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 749 | $18.02 | $13,498.48 |
DisclosureSEC source: 0001689375-24-000064 · wk-form4_1730929001.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 600 | $18.00 | $10,800.00 |
DisclosureSEC source: 0001689375-24-000057 · wk-form4_1729283492.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,216 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,642 | $15.09 | $39,862.23 |
DisclosureSEC source: 0001689375-24-000053 · wk-form4_1726000325.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,816 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 600 | $15.24 | $9,141.36 |
DisclosureSEC source: 0001689375-24-000053 · wk-form4_1726000325.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,458 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.08 to $15.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2024 Filed Sep 5, 2024 22:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 167 | $15.13 | $2,526.04 |
DisclosureSEC source: 0001689375-24-000050 · wk-form4_1725576454.xml · nonDerivative · entry 5 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,058 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 22:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 955 | $15.42 | $14,729.35 |
DisclosureSEC source: 0001689375-24-000050 · wk-form4_1725576454.xml · nonDerivative · entry 4 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,225 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 14 | $17.70 | $247.83 |
DisclosureSEC source: 0001689375-24-000050 · wk-form4_1725576454.xml · nonDerivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,180 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 151 | $16.93 | $2,555.75 |
DisclosureSEC source: 0001689375-24-000050 · wk-form4_1725576454.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,194 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 469 | $15.76 | $7,391.96 |
DisclosureSEC source: 0001689375-24-000050 · wk-form4_1725576454.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,345 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.49 to $16.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 20:43 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 638 | $18.00 | $11,484.00 |
DisclosureSEC source: 0001689375-24-000041 · wk-form4_1721162618.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,814 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 20:43 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 600 | $18.00 | $10,800.00 |
DisclosureSEC source: 0001689375-24-000041 · wk-form4_1721162618.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,452 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. Read SEC document |
| May 20, 2024 Filed May 20, 2024 21:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 9,675 | $15.19 | $146,943.90 |
DisclosureSEC source: 0001689375-24-000031 · wk-form4_1716240336.xml · nonDerivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,052 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 17, 2024 Filed May 20, 2024 21:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 8,305 | $15.14 | $125,750.99 |
DisclosureSEC source: 0001689375-24-000031 · wk-form4_1716240336.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,727 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001689375-24-000031 · wk-form4_1716240336.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,032 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 00:44 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,505 | $12.28 | $18,479.59 |
DisclosureSEC source: 0001689375-24-000003 · wk-form4_1709685871.xml · nonDerivative · entry 4 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,032 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:44 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 414 | $13.37 | $5,534.06 |
DisclosureSEC source: 0001689375-24-000003 · wk-form4_1709685871.xml · nonDerivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,537 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:44 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 347 | $12.42 | $4,310.78 |
DisclosureSEC source: 0001689375-24-000003 · wk-form4_1709685871.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,951 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $13.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:44 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 66,800 | $0.00 Strike: $13.73 | $0.00 |
DisclosureSEC source: 0001689375-24-000003 · wk-form4_1709685871.xml · derivative · entry 5 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,800 Underlying: Common Stock · 66,800 shares Expires 2034-03-01 F6 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2028. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:44 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 44,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-24-000003 · wk-form4_1709685871.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,298 F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:09 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 449 | $14.46 | $6,493.66 |
DisclosureSEC source: 0001689375-23-000063 · wf-form4_169403458332193.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,198 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:09 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $15.41 | $0.00 |
DisclosureSEC source: 0001689375-23-000063 · wf-form4_169403458332193.xml · derivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-09-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:09 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000063 · wf-form4_169403458332193.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,647 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 14,852 | $18.04 | $267,915.23 |
DisclosureSEC source: 0001689375-23-000046 · wf-form4_168919391527267.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,447 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,026 | $18.00 | $54,474.05 |
DisclosureSEC source: 0001689375-23-000046 · wf-form4_168919391527267.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,299 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 22:06 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,961 | $18.00 | $71,315.82 |
DisclosureSEC source: 0001689375-23-000031 · wf-form4_168194195395803.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,325 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,058 | $11.60 | $12,268.78 |
DisclosureSEC source: 0001689375-23-000014 · wf-form4_167787931361377.xml · nonDerivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,486 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000014 · wf-form4_167787931361377.xml · derivative · entry 3 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2033-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 28,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000014 · wf-form4_167787931361377.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,544 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:50 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000029 · wf-form4a_168194101787371.xml · derivative · entry 2 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:50 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000029 · wf-form4a_168194101787371.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,286 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 5,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-097876 · tm2225276-2_4seq1.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,144 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:16 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 34,763 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001104659-22-077703 · tm2220515-2_4seq1.xml · derivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,763 Underlying: Common Stock · 34,763 shares Expires 2032-07-01 F1 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on July 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on July 1, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.